MindMed
MNMDNASDAQTicker changedDeveloping pharmaceutically optimized psychedelic-derived therapies. Lead compound MM120 is a purified, precisely dosed form of lysergide (LSD) in an orally disintegrating tablet, targeting anxiety and depression without the recreational baggage — administered in a clinical setting under medical supervision.
Drafted with AI assistance from public sources and not individually reviewed by an editor; last updated 2026-03-26. Published by ClinicalInvestor. Educational analysis only. Read the editorial policy and disclosures.
text updated 2026-03-26, 236 days ago · archived: kept for reference, not maintained · where each field comes from
Pipeline at the time of the last update
| Drug | Indication | Phase | Expected data | |
|---|---|---|---|---|
| MM120 (lysergide D-tartrate ODT) | Generalized anxiety disorder (GAD) | Phase 3 | Voyage: H1 2026, Panorama: H2 2026 | ▼ |
| MM120 | Major depressive disorder (MDD) | Phase 2 | 2027+ | ▼ |
Comparable companies
Disclaimer: This page is for informational and educational purposes only and does not constitute financial advice or a recommendation to buy or sell securities. Clinical trial analysis reflects publicly available data and AI-generated interpretations. Biotech investing carries significant risk including potential total loss of investment. Always verify critical claims through primary sources and consult a qualified financial advisor. Some links on this page are affiliate links. Review our editorial policy and disclosures.